Navigation Links
Mylan Receives Approval for Generic Version of Precose® Tablets
Date:1/18/2011

PITTSBURGH, Jan. 18, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Acarbose Tablets, 25 mg, 50 mg and 100 mg, the generic version of Bayer's Precose® Tablets, a treatment to be used with diet and exercise to improve glycemic control in adults with type 2 diabetes.

Acarbose Tablets had U.S. sales of approximately $23 million for the 12 months ending Sept. 30, 2010, according to IMS Health. The product is available for immediate shipment.

Currently, Mylan has 169 ANDAs pending FDA approval representing $99.5 billion in annual sales, according to IMS Health. Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $24 billion in annual brand sales, for the 12 months ending June 30, 2010, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Announces Voluntary De-listing of 1.25% Senior Convertible Notes Due 2012 from Nasdaq
2. Mylans Dey Pharma Partners with Meda to Market EpiPen® Auto-Injector in Europe
3. Mylan Confirms First-to-File Patent Challenge Relating to Orapred ODT®
4. Mylan Receives Approval for Generic Version of Adalat® CC Tablets
5. Mylan Announces the Conversion of its Preferred Stock into Common Stock
6. Mylan Announces Final Conversion Rate for Mandatory Convertible Preferred Stock
7. Third Circuit Denies Mylan Motion for Interim Injunction
8. Mylan Reports Adjusted Diluted EPS of $0.43; Reaffirms 2010 Adjusted Diluted EPS Guidance of $1.55 - $1.65
9. Mylan Declares Quarterly Preferred Stock Dividend
10. Mylan to Appeal Court Decision in Generic Paroxetine Hydrochloride CR Case
11. Mylan Receives Approvals for Generic Versions of Hyzaar® and Cozaar®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... 10, 2017 Radiology has become the number ... have also spiraled to the number one ranking as ... than ever before as the most complete and reliable ... with lower back pain an MRI may confirm a ... pain, resulting in entirely different treatment protocols.  In these ...
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals Inc. ... a clinical-stage pharmaceutical company focused on the development ... the Canadian Intellectual Property Office has granted Oramed ... Administration of Exenatide". The patent covers Oramed,s invention ... GLP-1 is an incretin hormone that stimulates ...
(Date:5/6/2017)... --  Provista , a proven leader in the supply chain ... Jim Cunniff as the company,s new president and ... to Provista, including most recently serving as the president and ... . He assumed his new role with Provista on May ... Provista," says Jody Hatcher , president, Sourcing and Collaboration ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... NucleusHealth ™, advancing clinical ... U.S. Food and Drug Administration (FDA) 510(k) clearance for its ... platform for medical image management. At the core is patented streaming technology that ...
(Date:5/24/2017)... Cortland, OH (PRWEB) , ... May 24, 2017 , ... ... in Cortland, OH, can now meet with Dr. Joseph Bedich for a consultation, ... smiles while simultaneously improving their oral health and functionality. , Dr. Bedich ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Curry Leavitt, a noted ... Periodontal Practice) continuing education (CE) series. As a compassionate and dedicated clinician, Dr. ... attending numerous CE courses each year. His recent course, Course II of HP3, ...
(Date:5/24/2017)... ... May 24, 2017 , ... Accordant ... its solutions portfolio. ExtraHop delivers an analytics-first approach, layered with machine learning, that ... from the datacenter to the cloud to the edge. Through the new partnership, ...
(Date:5/24/2017)... ... 2017 , ... Rob Lowe is a sought after actor, and also serves ... the public important topics from all aspects of life, and a new segment is ... feet and ankles. , Podiatry is essential to people’s overall well-being, and if viewers ...
Breaking Medicine News(10 mins):